Phase III clinical trials of the cell differentiation agent-2 (CDA-2): Therapeutic efficacy on breast cancer, non-small cell lung cancer and primary hepatoma1

Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG island methylation has non-random and tumor-type-specific patterns. Nat Genet. 2000;24:132–138.

Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249–255.

Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225–3229.

Paz MF, Fraga MF, Avila S, et al. A systemic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003; 63:1114–1121.

Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004;64: 5527–5534.

Parrella P, Poeta ML, Gallo AP, et al. Nonrandom distribution of aberrant methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 2004; 10:5349–5354.

Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Intl J Exp Clin Chemother. 1989;2:187–199.

Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Seminars Cancer Biol. 2002; 12:339–346.

Kalebic T. Epigenetic changes: potential therapeutic targets. Ann NY Acad Sci.2003;983:278–285.

Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003;63:7089–7093.

Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitions and DNA methyltransferase inhibitons in the treatment of human cancer cells. Curr Med Chem Anti-cancer Agents. 2003;3:187–199.

Baiocchi M, Rico CR, Pietro RP, et al. 5-Azacytidine reactivates the erythroid differentiation potential of the myeloidrestricted murine cell line 32D Ro. Exp Cell Res. 2003; 285: 258–267.

Gilbert J, Core SD, Herman JG, et al. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res. 2004;10:4589–4596.

Chen RZ, Pettersson U, Beard L, et al. DNA Hypomethylation leads to elevated mutation rates. Nature. 1998;395:89–93.

Eden A, Gendet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455.

Lin CH, Hsieh SY, Sheen IS, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61:4238–4243.

Gandet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489–492.

Widschwendter M, Jiang G, Words C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004 ;64:4472–4480.

Nishiagki M, Aoyagi K, Danjoh I, et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 2005; 65:2115–2124.

Liau MC, Chang CF, Sannders GF, et al. S-adenosylhomocysteine hydrolases as primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208:261–272.

Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepato-carcinogenesis and in resulting carcinomas. Cancer Res. 1979; 39: 2113–2119.

Liau MC, Chang CF, Giovanella BC. Demonstratron of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980; 64:1071–1075.

Liau MC, Burzynski SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res. 1986;12(Suppl.l):77–86.

Liau MC. Abnormal methylation enzymes: a selective molecular target for differentiation therapy of cancer. Chin Pharm J. 2004; 56: 57–67.

Salem C, Liang G, Tsai YC, et al. Progressive increase in de novo methylation of CpG islands in bladder cancer. Cancer Res. 2000; 60:2473–2476.

Eads CA, Lord RV, Wickramasingle U, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61:3410–3418.

Mehrotra J, Vali M, McVeigh M, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res. 2004;10:3104–3109.

Kishi K, Doki Y, Yano M, et al. Reduced hMLHl expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003;9:4368–4375.

Gifford G, Paul J, Vasey PA, et al. The acquisition of h MLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004; 10:4420–4426.

Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 1989;49:5829–5836.

Liau MC, Luong Y, Liau CP, et al. Prevention of drug induced DNA hypermethylation by antineoplaston components. Intl J Exp Clin Chemother. 1992;5:19–27.

Liau MC, Lee SS, Burzynski SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by Antineoplaston A5. Intl J Tiss React 1990;12(Suppl.l):27–36.

Liau MC, Huang LJ, Lee JH, et al. Development of differentiation helper inducers for the differentiation therapy of cancer. Chin Pharm J. 1998;50:289–303.

Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11:166–168.

Liau MC, Szopa M, Burzynski B, et al. Chemo-surveillance: a novel concept of natural defense mechanism against cancer. Drugs Exp Clin Res. 1987;13:(Suppl.l): 77–82.

Liu YK, Li Y, Ma X, et al. Regulation of liver cancer related genes and alpha fetal protein expression by CDA -2. Bull Chin Cancer. 2002;11:169–172.

Sun JJ, Zhou XD, Liu YK, et al. Prevention of metastasis and recurrence in xenografted nude mice by differentiation inducer CDA-2. Chin Hepatobill J. 1999;5:14–16.

Xu JY, Zhou Q, Lu P, et al. Induction of apoptosis and reversal of drug resistance in human tumor cell line KBv200 by cell differentiation agent-2 (CDA-2). Chin J Intern Med. 2000;39:37–39.

Liao SK. Abrogation of telomerese activity by CDA-2. In: Liau MC. Smart Anticancer Drug CDA-2. Taipei, Taiwan: Shymou Publishing Co. 1999;188–190.

Meng ZQ, Huang, WX, Wang ZJ. Phase II clinical trial of CDA-2 on breast cancer. Bull Chin Cancer. 2002;11:113–114.

Gao YT, Shi SQ, Gu FL, et al. The effect of CDA -2 on advanced liver cancer in 15 cases. Bull Chin Cancer. 2002; 11:110–112.

Feng FY, Li Q, Wang ZJ. Effect of uroacitides in improving quality of life of advanced cancer patients. Chin J Clin Rehab. 2004;8:384–385.

Chen ZS, Ni M, Cheng HH, et al. Therapeutic efficacy of CDA-2 on advanced cancer patients: a comparison with cytotoxic chemotherapy. Chin J Clin Oncol Rehab. 1999;6:84–87.

Lai TY, Wu YW, Lin WC. Effect of an urinary preparation on acute liver injury induced by carbon tetrachloride. Chin Pharm J. 1998; 50:175–187.

Yen A. Control of HL -60 myeloid differentiation: evidence of uncoupled growth and differentiation, S-phase specificity, and two step regulation. Exp Cell Res. 1995;156:198–203.

Castro-Munezledo F, Beltran-Langarice K, Kuri-Harcnch W. Commitemt of 3T3 -F442A cells to adipocyte differentiation takes place during the first 24–34h after adipogenic stimulation: TNF inhibits commitemt. Exp Cell Res. 2003;284:161–170.